false 2025 Q3 --04-30 0001699709 0 0 0 0001699709 2024-05-01 2025-01-31 0001699709 2025-02-26 0001699709 2025-01-31 0001699709 2024-04-30 0001699709 2024-11-01 2025-01-31 0001699709 2023-11-01 2024-01-31 0001699709 2023-05-01 2024-01-31 0001699709 us-gaap:CommonStockMember 2024-04-30 0001699709 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0001699709 YJGJ:SharesToBeIssuedMember 2024-04-30 0001699709 us-gaap:RetainedEarningsMember 2024-04-30 0001699709 us-gaap:CommonStockMember 2024-07-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2024-07-31 0001699709 YJGJ:SharesToBeIssuedMember 2024-07-31 0001699709 us-gaap:RetainedEarningsMember 2024-07-31 0001699709 2024-07-31 0001699709 us-gaap:CommonStockMember 2024-10-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001699709 YJGJ:SharesToBeIssuedMember 2024-10-31 0001699709 us-gaap:RetainedEarningsMember 2024-10-31 0001699709 2024-10-31 0001699709 us-gaap:CommonStockMember 2023-04-30 0001699709 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0001699709 YJGJ:SharesToBeIssuedMember 2023-04-30 0001699709 us-gaap:RetainedEarningsMember 2023-04-30 0001699709 2023-04-30 0001699709 us-gaap:CommonStockMember 2023-07-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2023-07-31 0001699709 YJGJ:SharesToBeIssuedMember 2023-07-31 0001699709 us-gaap:RetainedEarningsMember 2023-07-31 0001699709 2023-07-31 0001699709 us-gaap:CommonStockMember 2023-10-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0001699709 YJGJ:SharesToBeIssuedMember 2023-10-31 0001699709 us-gaap:RetainedEarningsMember 2023-10-31 0001699709 2023-10-31 0001699709 us-gaap:CommonStockMember 2024-05-01 2024-07-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2024-05-01 2024-07-31 0001699709 YJGJ:SharesToBeIssuedMember 2024-05-01 2024-07-31 0001699709 us-gaap:RetainedEarningsMember 2024-05-01 2024-07-31 0001699709 2024-05-01 2024-07-31 0001699709 us-gaap:CommonStockMember 2024-08-01 2024-10-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2024-08-01 2024-10-31 0001699709 YJGJ:SharesToBeIssuedMember 2024-08-01 2024-10-31 0001699709 us-gaap:RetainedEarningsMember 2024-08-01 2024-10-31 0001699709 2024-08-01 2024-10-31 0001699709 us-gaap:CommonStockMember 2024-11-01 2025-01-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-01-31 0001699709 YJGJ:SharesToBeIssuedMember 2024-11-01 2025-01-31 0001699709 us-gaap:RetainedEarningsMember 2024-11-01 2025-01-31 0001699709 us-gaap:CommonStockMember 2023-05-01 2023-07-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2023-05-01 2023-07-31 0001699709 YJGJ:SharesToBeIssuedMember 2023-05-01 2023-07-31 0001699709 us-gaap:RetainedEarningsMember 2023-05-01 2023-07-31 0001699709 2023-05-01 2023-07-31 0001699709 us-gaap:CommonStockMember 2023-08-01 2023-10-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2023-08-01 2023-10-31 0001699709 YJGJ:SharesToBeIssuedMember 2023-08-01 2023-10-31 0001699709 us-gaap:RetainedEarningsMember 2023-08-01 2023-10-31 0001699709 2023-08-01 2023-10-31 0001699709 us-gaap:CommonStockMember 2023-11-01 2024-01-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2023-11-01 2024-01-31 0001699709 YJGJ:SharesToBeIssuedMember 2023-11-01 2024-01-31 0001699709 us-gaap:RetainedEarningsMember 2023-11-01 2024-01-31 0001699709 us-gaap:CommonStockMember 2025-01-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0001699709 YJGJ:SharesToBeIssuedMember 2025-01-31 0001699709 us-gaap:RetainedEarningsMember 2025-01-31 0001699709 us-gaap:CommonStockMember 2024-01-31 0001699709 us-gaap:AdditionalPaidInCapitalMember 2024-01-31 0001699709 YJGJ:SharesToBeIssuedMember 2024-01-31 0001699709 us-gaap:RetainedEarningsMember 2024-01-31 0001699709 2024-01-31 0001699709 YJGJ:NutripeakTradingCorporationMember 2024-05-01 2025-01-31 0001699709 YJGJ:NutripeakTradingCorporationMember 2025-01-31 0001699709 YJGJ:ConsultancyServiceFeeIncomeMember us-gaap:TransferredOverTimeMember 2024-11-01 2025-01-31 0001699709 YJGJ:ConsultancyServiceFeeIncomeMember us-gaap:TransferredOverTimeMember 2023-11-01 2024-01-31 0001699709 YJGJ:ConsultancyServiceFeeIncomeMember us-gaap:TransferredOverTimeMember 2024-05-01 2025-01-31 0001699709 YJGJ:ConsultancyServiceFeeIncomeMember us-gaap:TransferredOverTimeMember 2023-05-01 2024-01-31 0001699709 YJGJ:SalesOfHealthcareProductsMember us-gaap:TransferredAtPointInTimeMember 2024-11-01 2025-01-31 0001699709 YJGJ:SalesOfHealthcareProductsMember us-gaap:TransferredAtPointInTimeMember 2023-11-01 2024-01-31 0001699709 YJGJ:SalesOfHealthcareProductsMember us-gaap:TransferredAtPointInTimeMember 2024-05-01 2025-01-31 0001699709 YJGJ:SalesOfHealthcareProductsMember us-gaap:TransferredAtPointInTimeMember 2023-05-01 2024-01-31 0001699709 YJGJ:ConsultingServiceIncomeMember YJGJ:HealthcareSegmentMember 2024-11-01 2025-01-31 0001699709 YJGJ:ConsultingServiceIncomeMember YJGJ:ConsultingServiceSegmentMember 2024-11-01 2025-01-31 0001699709 YJGJ:ConsultingServiceIncomeMember 2024-11-01 2025-01-31 0001699709 YJGJ:SaleOfHealthcareProductsMember YJGJ:HealthcareSegmentMember 2024-11-01 2025-01-31 0001699709 YJGJ:SaleOfHealthcareProductsMember YJGJ:ConsultingServiceSegmentMember 2024-11-01 2025-01-31 0001699709 YJGJ:SaleOfHealthcareProductsMember 2024-11-01 2025-01-31 0001699709 YJGJ:HealthcareSegmentMember 2024-11-01 2025-01-31 0001699709 YJGJ:ConsultingServiceSegmentMember 2024-11-01 2025-01-31 0001699709 YJGJ:ConsultingServiceIncomeMember YJGJ:HealthcareSegmentMember 2024-05-01 2025-01-31 0001699709 YJGJ:ConsultingServiceIncomeMember YJGJ:ConsultingServiceSegmentMember 2024-05-01 2025-01-31 0001699709 YJGJ:ConsultingServiceIncomeMember 2024-05-01 2025-01-31 0001699709 YJGJ:SaleOfHealthcareProductsMember YJGJ:HealthcareSegmentMember 2024-05-01 2025-01-31 0001699709 YJGJ:SaleOfHealthcareProductsMember YJGJ:ConsultingServiceSegmentMember 2024-05-01 2025-01-31 0001699709 YJGJ:SaleOfHealthcareProductsMember 2024-05-01 2025-01-31 0001699709 YJGJ:HealthcareSegmentMember 2024-05-01 2025-01-31 0001699709 YJGJ:ConsultingServiceSegmentMember 2024-05-01 2025-01-31 0001699709 country:CN 2024-11-01 2025-01-31 0001699709 country:CN 2023-11-01 2024-01-31 0001699709 country:CN 2024-05-01 2025-01-31 0001699709 country:CN 2023-05-01 2024-01-31 0001699709 country:HK 2024-11-01 2025-01-31 0001699709 country:HK 2023-11-01 2024-01-31 0001699709 country:HK 2024-05-01 2025-01-31 0001699709 country:HK 2023-05-01 2024-01-31 0001699709 YJGJ:UnitesStatesOfAmericaMember 2024-11-01 2025-01-31 0001699709 YJGJ:UnitesStatesOfAmericaMember 2023-11-01 2024-01-31 0001699709 YJGJ:UnitesStatesOfAmericaMember 2024-05-01 2025-01-31 0001699709 YJGJ:UnitesStatesOfAmericaMember 2023-05-01 2024-01-31 0001699709 YJGJ:QiupingLuMember 2024-06-30 0001699709 YJGJ:QiupingLuMember 2024-06-01 2024-06-30 0001699709 YJGJ:QiupingLuMember 2024-08-31 0001699709 YJGJ:QiupingLuMember 2024-08-01 2024-08-31 0001699709 YJGJ:QiupingLuMember 2024-09-30 0001699709 YJGJ:QiupingLuMember 2024-09-01 2024-09-30 0001699709 YJGJ:SteveNiuMember YJGJ:Contract2024Member 2024-01-04 2024-01-31 0001699709 YJGJ:SteveNiuMember YJGJ:Contract2024Member 2024-05-01 2025-01-31 0001699709 YJGJ:SteveNiuMember YJGJ:Contract2024Member 2023-05-01 2024-01-31 0001699709 YJGJ:SteveNiuMember YJGJ:Contract2024Member 2025-01-31 0001699709 YJGJ:SteveNiuMember YJGJ:Contract2024Member 2024-04-30 0001699709 YJGJ:SteveNiuMember YJGJ:Contract2025Member 2024-05-01 2025-01-31 0001699709 YJGJ:SteveNiuMember YJGJ:Contract2025Member 2025-01-31 0001699709 YJGJ:SteveNiuMember YJGJ:Contract2025Member 2024-04-30 0001699709 YJGJ:PurchasesMember us-gaap:ProductConcentrationRiskMember YJGJ:OneVendorMember 2024-11-01 2025-01-31 0001699709 YJGJ:PurchasesMember us-gaap:ProductConcentrationRiskMember YJGJ:OneVendorMember 2024-05-01 2025-01-31 0001699709 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerCMember 2024-11-01 2025-01-31 0001699709 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerCMember 2025-01-31 0001699709 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerDMember 2024-11-01 2025-01-31 0001699709 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerDMember 2025-01-31 0001699709 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerEMember 2024-11-01 2025-01-31 0001699709 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerEMember 2025-01-31 0001699709 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomersCDAndEMember 2024-11-01 2025-01-31 0001699709 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomersCDAndEMember 2025-01-31 0001699709 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerAMember 2024-05-01 2025-01-31 0001699709 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerAMember 2025-01-31 0001699709 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerBMember 2024-05-01 2025-01-31 0001699709 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerBMember 2025-01-31 0001699709 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerCMember 2024-05-01 2025-01-31 0001699709 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomerDMember 2024-05-01 2025-01-31 0001699709 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomersABCAndDMember 2024-05-01 2025-01-31 0001699709 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember YJGJ:CustomersABCAndDMember 2025-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended January 31, 2025

☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

Commission File Number: 333-218733

Yijia Group Corp.

(Exact name of registrant as specified in its charter)

Nevada	35-2583762
(State or Other Jurisdiction of Incorporation or Organization)	(IRS Employer Identification Number)

39 E Broadway, Suite 603, New York, NY 10002	82801
(Address of principal executive offices)	(Zip Code)

Tel: +1-516-886-8888

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or . See the definitions of ” large accelerated filer “, “accelerated filer”, “non-accelerated filer”, “emerging growth company” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒

Emerging growth company ☐

Smaller reporting company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the issuer’s common stock issued and outstanding was 25,012,270, as of February 26, 2025.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

		Page

PART I	FINANCIAL INFORMATION:

Item 1.	Financial Statements	3

	Unaudited Condensed Consolidated Balance Sheets as of January 31, 2025 and April 30, 2024	4

	Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months ended January 31, 2025 and 2024	5

	Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the Nine Months Ended January 31, 2025 and 2024	6

	Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months ended January 31, 2025 and 2024	7

	Notes to the Unaudited Condensed Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23

Item 4.	Controls and Procedures	23

PART II	OTHER INFORMATION:

Item 1.	Legal Proceedings	24

Item 1A	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3.	Defaults Upon Senior Securities	24

Item 4.	Mine Safety Disclosures	24

Item 5.	Other Information	24

Item 6.	Exhibits	24

Signatures		25

PART 1 – FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

The accompanying interim consolidated financial statements of Yijia Group Corp. (“the Company”, “we”, “us” or “our”) have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with United States generally accepted principles have been condensed or omitted pursuant to such rules and regulations.

The interim consolidated financial statements are condensed and should be read in conjunction with the Company’s latest annual consolidated financial statements.

In the opinion of management, the consolidated financial statements contain all material adjustments, consisting only of normal adjustments considered necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

YIJIA GROUP CORP.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


	January 31, 2025		April 30, 2024
	(Unaudited)
ASSETS
Current assets:
Cash	$	405,173	$	593,036
Accounts receivable		54,018		–
Advances to vendors		671,782		460,870
Inventories		186,727		132,873
Other current assets		3,441		6,079
Total current assets		1,321,141		1,192,858

TOTAL ASSETS	$	1,321,141	$	1,192,858

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
Current Liabilities:
Accounts payable and accrued expenses	$	72,181	$	60,749
Other current liabilities		2,795		8,302
Amounts due to a related party		102,000		3,000
Income tax payable		35,813		64,869
Total current liabilities		212,789		136,920

TOTAL LIABILITIES		212,789		136,920

Commitments and Contingencies		–		–

Shareholders’ equity:
Ordinary shares, $0.001 par value; 75,000,000 shares authorized; 25,012,270 shares issued and outstanding as of January 31, 2025 and April 30, 2024		25,012		25,012
Additional paid in capital		1,012,971		1,012,971
Shares to be issued – 50,000 and 20,000 shares of ordinary shares		3,000		1,000
Retained earnings		67,369		16,955

Total Shareholders’ Equity		1,108,352		1,055,938

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	1,321,141	$	1,192,858

The accompanying notes are an integral part of these interim unaudited consolidated financial statements.

YIJIA GROUP CORP.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2025 AND 2024 (UNAUDITED)


	Three months ended January 31,						Nine months ended January 31,
	2025			2024			2025			2024

Revenue, net	$	308,318		$	26,100		$	708,913		$	26,100

Cost of revenue		(119,006	)		–			(290,594	)		–

Gross profit		189,312			26,100			418,319			26,100

Operating expenses
Sales and distribution expenses		(300	)		–			(7,489	)		–
Personnel and benefit costs		(49,471	)		–			(156,423	)		–
General and administrative expenses		(30,667	)		(20,152	)		(128,347	)		(53,154	)
Total operating expenses		(80,438	)		(20,152	)		(292,259	)		(53,154	)

Income (loss) from operations		108,874			5,948			126,060			(27,054	)

Other income (expense):
Other income		196			–			496			–
Interest expenses		(813	)		–			(2,938	)		–
Total other expense, net		(617	)		–			(2,442	)		–

Income (loss) before income tax		108,257			5,948			123,618			(27,054	)

Income tax expense		(35,279	)		–			(73,204	)		–

Net income (loss)	$	72,978		$	5,948		$	50,414		$	(27,054	)

Income (loss) per share, basic and diluted	$	0.00		$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average number of shares outstanding, basic and diluted		25,012,270			6,079,305			25,012,270			25,012,270

The accompanying notes are an integral part of these interim unaudited consolidated financial statements.

YIJIA GROUP CORP.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)

FOR THE NINE MONTHS ENDED JANUARY 31, 2025 AND 2024 (UNAUDITED)


	Ordinary shares
	No. of shares		Amount		Additional paid-in capital		Shares to be issued		Retained earnings (accumulated deficit)			Total shareholders’ equity (deficit)

Balance as of May 1, 2024		25,012,270	$	25,012	$	1,012,971	$	1,000	$	16,955		$	1,055,938

Share-based compensation – 15,000 shares		–		–		–		750		–			750
Net loss for the period		–		–		–		–		(55,211	)		(55,211	)

Balance as of July 31, 2024		25,012,270	$	25,012	$	1,012,971	$	1,750	$	(38,256	)	$	1,001,477

Share-based compensation – 15,000 shares		–		–		–		750		–			750
Net income for the period		–		–		–		–		32,647			32,647

Balance as of October 31, 2024		25,012,270	$	25,012	$	1,012,971	$	2,500	$	(5,609	)	$	1,034,874

Share-based compensation – 15,000 shares		–		–		–		500		–			500
Net income for the period		–		–		–		–		72,978			72,978

Balance as of January 31, 2025		25,012,270	$	25,012	$	1,012,971	$	3,000	$	67,369		$	1,108,352



Balance as of May 1, 2023		5,871,250	$	5,871	$	58,824	$	–	$	(123,910	)	$	(59,215	)

Net loss for the period		–		–		–		–		(24,247	)		(24,247	)

Balance as of July 31, 2023		5,871,250	$	5,871	$	58,824	$	–	$	(148,157	)	$	(83,462	)

Net loss for the period		–		–		–		–		(8,755	)		(8,755	)

Balance as of October 31, 2023		5,871,250	$	5,871	$	58,824	$	–	$	(156,912	)	$	(92,217	)

Shares issued under the private placement		19,141,020		19,141		937,910		–		–			957,051
Net income for the period		–		–		–		–		5,948			5,948

Balance as of January 31, 2024		25,012,270	$	25,012	$	996,734	$	–	$	(150,964	)	$	870,782

The accompanying notes are an integral part of these interim unaudited consolidated financial statements.

YIJIA GROUP CORP.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED JANUARY 31, 2025 AND 2024 (UNAUDITED)


	Nine months ended January 31,
	2025			2024

Cash flows from operating activities:
Net income (loss)	$	50,414		$	(27,054	)
Adjustment to reconcile net income (loss) used in operating activities:
Interest expenses		2,938			–
Share-based compensation		2,000			–
Changes in operating assets and liabilities:
Inventories		(53,854	)		–
Accounts receivable		(54,018	)		–
Advances to vendors		(210,912	)		–
Deposit and other receivables		–			(156,000	)
Other current assets		2,638			–
Accounts payable and accrued liabilities		8,995			(1,641	)
Other current liabilities		(5,507	)		–
Income tax payable		(29,056	)		–
Net cash used in operating activities		(286,363	)		(184,695	)

Cash flows from financing activity:
Interest paid		(500	)		–
Proceeds from private offering		–			957,051
Proceeds from a related party		99,000			27,272
Net cash provided by financing activity		98,500			984,323

Net change in cash		(187,863	)		799,628

Cash, beginning of period		593,036			8,728

Cash, end of period	$	405,173		$	808,356

SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid	$	500		$	–
Income taxes paid	$	–		$	–

The accompanying notes are an integral part of these interim unaudited consolidated financial statements.

YIJIA GROUP CORP.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

Yijia Group Corp. (“the Company” or “YJGJ”) was incorporated on January 25, 2017 under the laws of the State of Nevada, United States of America, formerly known as Soldino Group Corp.

The Company has currently commenced its operation in the rendering of consulting advisory services in management business, accounting and finance services; and provides healthcare products and health consultation services to domestic and international customers.

The details of the Company’s subsidiary are described below:


Name	Place of incorporation and kind of legal entity	Principal activities and place of operation	Particulars of issued/ registered share capital	Effective interest Held

Nutripeak Trading Corporation (“NTC”)	State of Nevada, United States of America, Corporation	Marketing and supplying healthcare products	100 shares of common stock, par value $1 per share	100%

YJGJ and its subsidiary are hereinafter referred to as (the “Company”).

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared by management in accordance with both accounting principles generally accepted in the United States (“GAAP”), and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and note disclosures normally included in audited consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. The unaudited condensed consolidated financial statements are presented in US dollars, which is the Company’s functional currency.

In the opinion of management, the condensed balance sheet as of April 30, 2024 which has been derived from audited consolidated financial statements and these unaudited condensed consolidated financial statements reflect all normal and considered necessary to state fairly the results for the periods presented. The results for the period ended January 31, 2025 are not necessarily indicative of the results to be expected for the entire fiscal year ending April 30, 2025 or for any future period.

These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Management’s Discussion and the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10-K for the year ended April 30, 2024, filed with the SEC on July 29, 2024.

Principles of Consolidation

The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiary. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation.

Reclassifications

Certain amounts on the prior year’s unaudited condensed consolidated balance sheets, unaudited condensed consolidated statements of operations and cash flows were reclassified to conform to current-year presentation, with no effect on ending stockholders’ equity.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Significant areas for which management uses estimates include:

	·	sales returns at point in time and allowances;
	·	inventory;
	·	income tax valuation allowances

These estimates require the use of judgment as future events, and the effect of these events cannot be predicted with certainty. The estimates will change as new events occur, as more experience is acquired and as more information is obtained. We evaluate and update our assumptions and estimates on an ongoing basis and we may consult outside experts to assist as considered necessary.

Revenue Recognition

	·	identify the contract with a customer;
	·	identify the performance obligations in the contract;
	·	determine the transaction price;
	·	allocate the transaction price to performance obligations in the contract; and
	·	recognize revenue as the performance obligation is satisfied.

Currently, the Company operates in two business segments.

The Consulting Service Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers.

The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. Revenue is recognized from the sale of their healthcare products upon delivery to the customers, whereas the title and risk of loss are fully transferred to customers.

Shipping term under Ex Works (“EXW”), the Company fulfills the obligation to deliver when the products are available on their premises, i.e. the warehouse. Customers are responsible for all transportation costs, risk of loss, and any other costs that point onward.

Revenue is earned from the rendering of consulting advisory services to customers. The Company recognizes services revenue over the period in which such services are performed and billed to the customer, pursuant to the fulfillment of service terms in the agreement.

Disaggregation of Revenue

The following table provides information about disaggregated revenue from customers into the nature of the products and services provided, and the related timing of revenue recognition:

Schedule of disaggregated revenue
		For the three months ended January 31,				For the nine months ended January 31,
Type of products or services	Timing of revenue recognition	2025		2024		2025		2024

Consultancy service fee income	Services transferred over time	$	7,000	$	26,100	$	10,838	$	26,100
Sales of healthcare products	Goods transferred at a point in time		301,318		–		698,075		–
		$	308,318	$	26,100	$	708,913	$	26,100

Recent Accounting Standard Adopted

In June 2016, the FASB issued ASC Update No. 2016-13, (Topic 326), Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments. This ASC update introduces new guidance for the accounting for credit losses on financial instruments within its scope. A new model, referred to as the current expected credit losses model, requires an entity to determine credit-related impairment losses for financial instruments held at amortized cost and to estimate these expected credit losses over the life of an exposure (or pool of exposures). The estimate of expected credit losses should consider both historical and current information, reasonable and supportable forecasts, as well as estimates of prepayments. The estimated credit losses and subsequent adjustment to such loss estimates, will be recorded through an allowance account which is deducted from the amortized cost of the financial instrument, with the offset recorded in current earnings. ASC No. 2016-13 also modifies the impairment model for available-for-sale debt securities. The new model will require an estimate of expected credit losses only when the fair value is below the amortized cost of the asset, thus the length of time the fair value of an available-for-sale debt security has been below the amortized cost will no longer affect the determination of whether a credit loss exists. In addition, credit losses on available-for-sale debt securities will be limited to the difference between the security’s amortized cost basis and its fair value. The updated guidance is effective for all entities other than public companies’ fiscal years beginning after December 15, 2022. The Company has adopted this accounting standard, effective April 1, 2023 and concluded that the adoption did not have a material effect on the Company’s financial condition, results of operations, and cash flows.

Accounting Standards Issued but Not Yet Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amended guidance requires incremental reportable segment disclosures, primarily about significant segment expenses. The amendments also require entities with a single reportable segment to provide all disclosures required by these amendments, and all existing segment disclosures. The amendments will be applied retrospectively to all prior periods presented in the financial statements and is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its unaudited condensed consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amended guidance enhances income tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This guidance requires disclosure of specific categories in the effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold. In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes. It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amended guidance is effective for fiscal years beginning after December 15, 2024. The guidance can be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to our unaudited condensed consolidated financial statements.

Except for the above-mentioned pronouncements, there are no new recently issued accounting standards that will have a material impact on the unaudited condensed consolidated balance sheets, statements of operations and cash flows.

NOTE 3 — SEGMENT REPORTING

Currently, the Company has two reportable business segments:

(i)	Consulting Service Segment, mainly provides consulting advisory services in management business, accounting and financial services; and
(ii)	Healthcare Segment, mainly provides healthcare products to customers, most of them are distributors.

In the following table, revenue is disaggregated by primary major product line, including a reconciliation of the disaggregated revenue with the reportable segments. For the three and nine months ended January 31, 2024, healthcare segment did not generate any revenue, all the revenue was generated from consulting service segment.


	Three Months ended January 31, 2025
	Healthcare Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	7,000		$	7,000
Sale of healthcare products		301,318			–			301,318
Total revenue		301,318			7,000			308,318

Cost of revenue:
Consulting service income		–			–			–
Sale of healthcare products		(119,006	)		–			(119,006	)
Total cost of revenue		(119,006	)		–			(119,006	)

Gross profit		182,312			7,000			189,312

Operating Expenses
Selling and distribution		(300	)		–			(300	)
Personal and benefit costs		(11,942	)		(37,529	)		(49,471	)
General and administrative		(4,734	)		(25,933	)		(30,667	)
Total operating expenses		(16,976	)		(63,462	)		(80,438	)

Segment income (loss)	$	165,336		$	(56,462	)	$	108,874

	Nine Months ended January 31, 2025
	Healthcare Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	10,838		$	10,838
Sale of healthcare products		698,075			–			698,075
Total revenue		698,075			10,838			708,913

Cost of revenue:
Consulting service income		–			–			–
Sale of healthcare products		(290,594	)		–			(290,594	)
Total cost of revenue		(290,594	)		–			(290,594	)

Gross profit		407,481			10,838			418,319

Operating Expenses
Selling and distribution		(7,489	)		–			(7,489	)
Personal and benefit costs		(48,404	)		(108,019	)		(156,423	)
General and administrative		(17,701	)		(110,646	)		(128,347	)
Total operating expenses		(73,594	)		(218,665	)		(292,259	)

Segment income (loss)	$	333,887		$	(207,827	)	$	126,060

The below revenues are based on the countries in which the customers are located. Summarized financial information concerning the geographic segments is shown in the following tables:


	Three Months ended January 31,				Nine Months ended January 31,
	2025		2024		2025		2024
China	$	7,000	$	–	$	86,200	$	–
Hong Kong		105,000		–		305,773		–
United States of America		196,318		26,100		316,760		26,100
	$	308,318	$	26,100	$	708,913	$	26,100

NOTE 4 － ACCOUNTS RECEIVABLE


	January 31, 2025		April 30, 2024

Accounts receivable	$	54,018	$	–
Less: allowance for expected credit losses		–		–
Total	$	54,018	$	–

For the nine months ended January 31, 2025 and 2024, no allowance of expected credit losses was recorded by the Company.

The Company generally conducts its business with creditworthy third parties. The Company determines, on a continuing basis, the probable losses and an allowance for expected credit losses, based on several factors including internal risk ratings, customer credit quality, payment history, historical bad debt/write-off experience and forecasted economic and market conditions. Accounts receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible. In addition, receivable balances are monitored on an ongoing basis and its exposure to bad debts is not significant.

NOTE 5 － INVENTORIES

Inventories comprised of the following:

Schedule of inventories
	January 31, 2025		April 30, 2024

Finished goods – Gene Code NR Capsules	$	186,727	$	132,873

For the nine months ended January 31, 2025 and 2024, no allowance for obsolete inventories was recorded by the Company.

NOTE 6－ INCOME TAX EXPENSE

The income tax provision for the nine months ended January 31, 2025 and 2024, consists of the following:

Schedule of income tax provision
	Nine Months ended January 31,
	2025		2024

Federal
Current	$	70,738	$	–
Deferred		–		–

State
Current		2,466		–
Deferred		–		–

Income tax provision	$	73,204	$	–

The deferred tax assets as of January 31, 2025 and April 30, 2024 were $90,810 and $46,969, respectively, which were fully reserved for valuation allowance. The net change in valuation allowance as of January 31, 2025 and April 30, 2024 was $43,841. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of January 31, 2025 and April 30, 2024. Up to six years since inception remain open for examination only by taxing authorities of US Federal and State of Nevada.

A reconciliation of the federal income tax rate to the Company’s effective tax rate for the nine months ended January 31, 2025 and 2024, consists of the following:


	Nine months ended January 31,
	2025		2024
Statutory federal income tax rate		21.0%		21.0%
Deferred tax asset		(34.2)%		21.0%
Change in valuation allowance		34.2%		(21.0)%
Adjustment to current year taxes		34.2%		(21.0)%
Effective Tax Rate		55.2%		–%

The effective tax rate differs from the statutory tax rate of 21% for the nine months ended January 31, 2025 and 2024, primarily due to the adjustment to current year taxes and valuation allowance on the deferred tax assets.

NOTE 7 － RELATED PARTY BALANCES AND TRANSACTIONS

Nature of relationships with related parties

Name of related party		Relationship with the Company
Qiuping Lu (“Ms. Lu”)		Chief Executive Officer and Director of the Company
Ruiming Zhou (“Mr. Zhou”)		Director of the Company
Steve Niu (“Mr. Niu”)		Chief Financial Officer of the Company
Triangle Accounting Inc.		An entity controlled by Steve Niu

In June 2024, Ms. Lu, Chief Executive Officer and Director of the Company, loaned the Company an aggregate principal amount of $50,000, which bears interest at a monthly rate of 0.5% and becomes payable upon maturity on December 3, 2024. The loan was mutually agreed to extend to mature on February 3, 2025.

In August 2024, Ms. Lu, Chief Executive Officer and Director of the Company, loaned the Company an aggregate principal amount of $50,000, which bears interest at a monthly rate of 0.5% and becomes payable upon maturity on April 13, 2025.

In September 2024, Ms. Lu, Chief Executive Officer and Director of the Company, loaned the Company an aggregate principal amount of $25,000, which bears interest at a monthly rate of 0.5% and becomes payable upon maturity on January 4, 2025.

On January 8, 2024, the Company granted 5,000 shares of common stocks issuable per month in total of 60,000 shares of common stock to the Chief Financial Officer - Steve Niu at fair value of $0.05 per share, subject to vesting condition in completion of one year of service. For the nine months ended January 31, 2025 and 2024, the Company recognized share-based compensation in the amount of $2,000 and $Nil, respectively. As of January 31, 2025 and April 30, 2024, the Company’s common stock issuable totaled 60,000 and 20,000 shares, respectively.

On January 1 2025, the Company renewed employment contract with Mr. Niu, which Mr. Niu shall continue serve as Chief Financial Officer with monthly compensation of $2,000 for his service. For the nine months ended January 31, 2025 and 2024, the Company recognized compensation in the amount of $2,000 and $Nil, respectively. As of January 31, 2025 and April 30, 2024, the Company’s salary payable to Mr. Niu was $2,000 and $Nil, respectively.

NOTE 8 － CONCENTRATIONS OF RISK

The Company is exposed to the following concentrations of risk:

(a)

Cash

The Company maintains cash with banks in the United States of America (“USA”). Should any bank holding cash become insolvent, or if the Company is otherwise unable to withdraw funds, the Company would lose the cash with that bank; however, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts. In the United States, the standard insurance amount is $250,000 per depositor in a bank insured by the Federal Deposit Insurance Corporation (“FDIC”).

Financial instruments that potentially subject the Company to significant concentrations of credit risk are cash. As of January 31, 2025 and April 30, 2024, $14,391.37 and $301,267 of the Company’s cash held by financial institutions were uninsured, respectively.

(a)	Major customers

For the three and nine months ended January 31, 2025, the individual customers who accounted for 10% of the Company’s revenue and its outstanding receivables balance at period-end rates, as presented as follows:

Schedule of concentrations risk
	Three months ended January 31, 2025				As of January 31, 2025
Customer	Revenue		Percentage of revenue		Accounts receivable

Customer C	$	141,000		45.73%	$	–
Customer D		105,000		34.06%		–
Customer E		35,318		11.46%		–

	$	281,318		91.25%	$	–

	Nine months ended January 31, 2025				As of January 31, 2025
Customer	Revenue		Percentage of revenue		Accounts receivable

Customer A	$	200,773		28.32%	$	–
Customer B		79,200		11.17%		54,018
Customer C		207,668		29.29%		–
Customer D		105,000		14.81%		–

	$	592,641		83.59%	$	54,018

These customers are located in Hong Kong, China and the United States of America.

For the nine months ended January 31, 2024, there is one customer who accounted for 10% or more of the Company’s revenue.

(b)	Major vendors

For the three and nine months ended January 31, 2025, there is one vendor who accounted for 100% and 100% of the Company’s purchase cost amounting to $119,006 and $290,594, respectively.

For the three and nine months ended January 31, 2024, there is no single vendor who accounted for more than 10% of the Company’s purchase.

The Company’s major vendors are located in United States of America.

NOTE 9－ COMMITMENTS AND CONTINGENCIES

As of January 31, 2025, the Company has no commitments or contingencies.

NOTE 10－ SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before the unaudited condensed consolidated financial statements are issued, the Company has evaluated all events or transactions that occurred after January 31, 2025, up to the date that the unaudited condensed consolidated financial statements were available to be issued.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our results of operations and financial condition should be read together with our unaudited condensed consolidated financial statements and the notes thereto, which are included elsewhere in this report and our Annual Report on Form 10-K for the fiscal year ended April 30, 2024 (the “Annual Report”) filed with SEC. Our financial statements have been prepared in accordance with U.S. GAAP. In addition, our financial statements and the financial information included in this report reflect our organizational transactions and have been prepared as if our current corporate structure had been in place throughout the relevant periods.

Forward looking statement notice

Statements made in this Form 10-Q that are not historical or current facts are “forward-looking statements” made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 (the “Act”) and Section 21E of the Securities Exchange Act of 1934. These statements often can be identified by the use of terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “approximate” or “continue,” or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management’s best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

Financial information contained in this report and in our financial statements is stated in United States dollars and are prepared in accordance with United States generally accepted accounting principles.

Corporate Overview

Yijia Group Corp. (“the Company” or “YJGJ”) was incorporated on January 25, 2017 under the laws of the State of Nevada, United States of America, formerly known as Soldino Group Corp.

Meanwhile, the Company continues to look for other opportunities which could potentially increase the profits of the Company in 2025.

Results of Operations

Currently, we commenced our operation in the rendering of business consulting service and marketing and supplying healthcare products to domestic and international customers.

The following table sets forth certain operational data for the three and nine months ended January 31, 2025 and 2024:

	Three Months Ended January 31,
	2025			2024
Revenues	$	308,318		$	26,100
Cost of revenue		(119,006	)		–
Gross profit		189,312			26,100
Total operating expenses		(80,438	)		(20,152	)
Income from operation		108,874			5,948
Other expense, net		(617	)		–
Income before income tax		108,257			5,948
Income tax expense		(35,279	)		–
Net income	$	72,978		$	5,948

	Nine Months Ended January 31,
	2025			2024
Revenues	$	708,913		$	26,100
Cost of revenue		(290,594	)		–
Gross profit		418,319			26,100
Total operating expenses		(292,259	)		(53,154	)
Income (loss) from operation		126,060			(27,054	)
Other expense, net		(2,442	)		–
Income (loss) before income tax		123,618			(27,054	)
Income tax expense		(73,204	)		–
Net income (loss)	$	50,414		$	(27,054	)

Revenue

For the three and nine months ended January 31, 2025, we generated revenues of $308,318 and $708,913, respectively. For the comparative three and nine months ended January 31, 2024, we generated revenues of $26,100 and $26,100, respectively. Our major customers are located in Hong Kong, China and the United States of America. Our revenue significantly increased by $282,218 and $682,813, or 1,081% and 2,616%, respectively due to the commencement of business of the healthcare products segment.

During the three and nine months ended January 31, 2025 and 2024, the nature of businesses and segment was shown as below:

Currently, the Company has two reportable business segments:

(i)	Consulting Service Segment, mainly provides consulting advisory services in management business, accounting and financial services; and
(ii)	Healthcare Segment, mainly provides healthcare products and healthcare consultation services to the customers.

In the following table, revenue is disaggregated by primary major product line, including a reconciliation of the disaggregated revenue with the reportable segments. For the three and nine months ended January 31, 2025, healthcare segment did not generate any revenue, and all the revenue was generated from consulting services segment.

	Three Months ended January 31, 2025
	Healthcare Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	7,000		$	7,000
Sale of healthcare products		301,318			–			301,318
Total revenue		301,318			7,000			308,318

Cost of revenue:
Consulting service income		–			–			–
Sale of healthcare products		(119,006	)		–			(119,006	)
Total cost of revenue		(119,006	)		–			(119,006	)

Gross profit		182,312			7,000			189,312

Operating Expenses
Selling and distribution		(300	)		–			(300	)
Personal and benefit costs		(11,942	)		(37,529	)		(49,471	)
General and administrative		(4,734	)		(25,933	)		(30,667	)
Total operating expenses		(16,976	)		(63,462	)		(80,438	)

Segment income (loss)	$	165,336		$	(56,462	)	$	108,874

	Nine Months ended January 31, 2025
	Healthcare Segment			Consulting Service Segment			Total
Revenue from external customers:
Consulting service income	$	–		$	10,838		$	10,838
Sale of healthcare products		698,075			–			698,075
Total revenue		698,075			10,838			708,913

Cost of revenue:
Consulting service income		–			–			–
Sale of healthcare products		(290,594	)		–			(290,594	)
Total cost of revenue		(290,594	)		–			(290,594	)

Gross profit		407,481			10,838			418,319

Operating Expenses
Selling and distribution		(7,489	)		–			(7,489	)
Personal and benefit costs		(48,404	)		(108,019	)		(156,423	)
General and administrative		(17,701	)		(110,646	)		(128,347	)
Total operating expenses		(73,594	)		(218,665	)		(292,259	)

Segment income (loss)	$	333,887		$	(207,827	)	$	126,060

The revenues presented below are based on the countries in which the customers are located. Summarized financial information concerning the geographic segments is shown in the following tables:

	Three Months ended January 31,				Nine Months ended January 31,
	2025		2024		2025		2024
China	$	7,000	$	–	$	86,200	$	–
Hong Kong		105,000		–		305,773		–
United States of America		196,318		26,100		316,760		26,100
	$	308,318	$	26,100	$	708,913	$	26,100

Cost of revenue

Cost of revenue as a percentage of net revenue was approximately 39% and 41% for the three and nine months ended January 31, 2025, respectively. No cost of revenue was incurred for the three and nine months ended January 31, 2024. Cost of revenue increased by $119,006 and $290,594, or 100% and 100%, respectively is exclusively attributable to the commencement of business of healthcare product segment.

Gross profit

For the three months ended January 31, 2025 and 2024, the gross profit was $189,312 and $26,100, respectively, and the gross profit margin was 61% and 100%, respectively. For the nine months ended January 31, 2025 and 2024, the gross profit was $418,319 and $26,100, respectively, and the gross profit margin was 59% and 100%, respectively. The increase in gross profit margin for the periods ended January 31, 2025, compared to the same periods in 2024, is primarily attributable to the commencement in sales of healthcare products.

Sales and distribution expenses

We incurred sales and distribution expenses of $300 and $Nil for the three months ended January 31, 2025 and 2024, respectively. We incurred sales and distribution expenses of $7,489 and $Nil for the nine months ended January 31, 2025 and 2024, respectively. The increase in sales and distribution expenses for the periods ended January 31, 2025, compared to the same periods in 2024, is primarily attributable to the increase in advertising expenses aligned with the newly healthcare products.

Personnel and benefit costs

We incurred personnel and benefit costs of $49,471 and $Nil for the three months ended January 31, 2025 and 2024, respectively. We incurred personnel and benefit costs of $156,423 and $Nil for the nine months ended January 31, 2025 and 2024, respectively. The increase in sales and distribution expenses for the periods ended January 31, 2025, compared to the same periods in 2024, is primarily attributable to the increase in the salaries of key management personnel.

General and administrative expenses

We incurred general and administrative expenses of $30,667 and $20,152 for the three months ended January 31, 2025 and 2024, respectively. General and administrative expenses increased by $10,515 or 52% for the three months ended January 31, 2025 compared to the same periods in 2024. We incurred general and administrative expenses of $128,347 and $53,154 for the nine months ended January 31, 2025 and 2024, respectively. General and administrative expenses increased by $75,193 or 141% compared to the same period in 2024. The increase in general and administrative expenses is primarily attributable to an increase in legal and professional fees.

Net income (loss)

As a result of the factors described above, we reported net income of $72,978 and $5,948 for the three months ended January 31, 2025 and 2024, respectively. For the nine months ended January 31, 2025 and 2024, the Company has a net income of $50,414 and a net loss of $27,054, respectively.

Liquidity and capital resources

On January 31, 2025, we had total current assets of $1,321,141, which consisted primarily of $405,173 in cash, $54,018 in accounts receivable, $671,782 in advances to vendor, $186,727 in inventories and $3,441 in other current assets. We had total current liabilities of $212,789, which consisted of $72,181 in accounts payable and accrued expenses, $2,795 in other current liabilities, $102,000 due to related parties and $35,813 in income tax payable.

On April 30, 2024, we had total current assets of $1,192,858, which consisted primarily of $593,036 in cash, $460,870 in advances to vendor, $132,873 in inventories and $6,079 in other current assets. We had total current liabilities of $136,920, which consisted of $60,749 in accounts payable and accrued expenses, $8,302 in other current liabilities, $3,000 due to related parties and $64,869 in income tax payable.

We have never paid dividends on our Common Stock. Our present policy is to apply cash to investments in product development, acquisitions or expansion; consequently, we do not expect to pay dividends on Common Stock in the foreseeable future.

Cash Flows

The following table sets forth a summary of our cash flows for the periods indicated:

	Nine Months ended
	January 31, 2025			January 31, 2024
Net cash used in operating activities	$	(286,363	)	$	(184,695	)
Net cash provided by financing activities		98,500			984,323

Operating Activities

For the nine months ended January 31, 2025, net cash used in operating activities was $286,363 which consisted primarily of a net income of $50,414, increase in accounts receivable of $54,018, increase in advances to vendor of $210,912, increase in inventories of $53,854, decrease in other current liabilities of $5,507 and decrease in income tax payable of $29,056. The amounts were partially offset by adjusted non-cash item consisting of share-based compensation of $2,000, interest expense of $2,938, decrease in other current assets of $2,638 and increase in accounts payable and accrued expenses of $8,995.

For the nine months ended January 31, 2024, net cash flows used in operating activities was $184,695, which consisted primarily of a net loss of $27,054, an increase in deposit and other receivables of $156,000 and a decrease in accrued liabilities and other payables of $1,641.

Financing Activities

For the nine months ended January 31, 2025, net cash provided by financing activities was $98,500, which consisted primarily of proceed from a related party of $99,000 and interest paid of $500.

For the nine months ended January 31, 2024, net cash provided by financing activities was $984,323, which consisted primarily of proceed from private offering of $957,051 and advances from related parties of $27,272.

Limited operating history; need for additional capital

There is no historical financial information about us upon which to base an evaluation of our performance. We are in a start-up stage of operations and have generated limited revenues since inception. We cannot guarantee that we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products.

Off-Balance Sheet Arrangements

As of January 31, 2025, the Company did not have any off-balance sheet arrangements that had or were reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Contractual Obligations and Commercial Commitments

We had no contractual obligations and commercial commitments as of January 31, 2025.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

None.

ITEM 4.

CONTROLS AND PROCEDURES

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of January 31, 2025. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

The matters involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our Board of Directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; and (2) ineffective controls over period end financial disclosure and reporting processes. The aforementioned material weaknesses were identified by our Chief Executive Officer and Chief Financial Officer in connection with the review of our financial statements as of January 31, 2025.

Management believes that the material weaknesses set forth in items (2) and (3) above did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our Board of Directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Changes in Internal Controls over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We are aware that any system of controls, however well designed and operated, can only provide reasonable, and not absolute, assurance that the objectives of the system are met, and that maintenance of disclosure controls and procedures is an ongoing process that may change over time.

PART II – OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are not currently a party to any legal proceedings, and we are not aware of any pending or potential legal actions.

ITEM 1A.

RISK FACTORS

The information to be reported under this Item is not required for smaller reporting companies.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

None.

ITEM 5.

OTHER INFORMATION

During the quarter ended January 31, 2025, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

ITEM 6.

EXHIBITS

The following exhibits are included as part of this report by reference:

31.1*		Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).
31.2*		Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).
32.1**		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

** Furnished herewith and not to be incorporated by reference into any filing of Yijia Group Corp. under the Securities Act or the Exchange Act whether made before or after the date of this Quarterly Report.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 17, 2025.

	YIJIA GROUP CORP.


	By:	/s/ Qiuping Lu
		Qiuping Lu, Chief Executive Officer

	By:	/s/ Steve Niu
		Steve Niu, Chief Financial Officer

YIJIA GROUP CORP. 10-Q